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Incidence and mortality data, stage of disease and treatment information for female breast cancer were obtained for the years 1975–
1999 for the former Yorkshire Regional Health Authority area, from the Northern and Yorkshire Cancer Registry and Information
Service. Deaths by age group and 3-year calendar period were separated into those occurring among cases diagnosed 0–2 and 3–4
years preceding death (short- and medium-term survivors, respectively), and among longer-term survivors and age-adjusted rates
were calculated separately by survival time. The 3-year survival of cases incident in 1991–1999 and in 1982–1990 were compared,
adjusting for stage and treatment. Breast cancer mortality in Yorkshire stopped increasing around 1983 and has since consistently
declined, primarily among short- and medium-term survivors. The 3-year survival was significantly improved in cases diagnosed in
1991–1999, compared with 1982–1990, in all age groups (hazard ratio (HR)¼0.75, 95% c.l. 0.71–0.78). The improvement was
least in the 65þ years age group (HR¼0.83, 95% c.l. 0.79–0.88), intermediate in the youngest (o50 years) cases (HR¼0.71, 95%
c.l. 0.63–0.80) and greatest in the age group 50–64 years, offered routine screening after 1988 (HR¼0.51, 95% c.l. 0.47–0.57). The
benefit for cases diagnosed in the 1990s persisted, but was reduced after adjustment for stage in cases o65 years, while it
disappeared in older cases (HR¼1.01). Below age 65 years, the use of systemic therapy increased substantially, but did not explain
the residual improvements in short-term prognosis. A greater decline in breast cancer mortality in Yorkshire from 1982 to 1984 was
observed among short- and medium-term, than in longer-term, survivors. Much of the improvement in survival in cases o65 years
could be attributed to a more favourable stage at diagnosis, whereas this accounted for nearly all the improvement in survival among
older cases. Systemic therapy had little or no impact on 3-year survival. Continuing declines in mortality can be expected in the
current decade, as a result of the long-term effects of both mammography screening and increased use of systemic therapy.
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In the mid-1980s, England and Wales had the highest age-
standardised mortality rate for female breast cancer in the world
(World Health Organisation, 1985, 1986, 1987), most likely the
result of relatively high incidence rates and poor prognosis of
disease at diagnosis. Decreases in breast cancer mortality rates
during the 1990s have been observed in several countries (Botha
et al, 2003), but the decline in the UK, that began in the mid-1980s,
has been dramatic (Beral et al, 1995; Quinn and Allen, 1995;
Hermon and Beral, 1996; Peto et al, 2000). This has largely been
attributed to improved prognosis, as there has been no evidence of
a decrease in the underlying risk of disease (Peto et al, 2000). The
main determinants of prognosis are early stage at diagnosis and
efficacy of treatment delivery. Assessment of the specific
quantitative impact of these two determinants requires informa-
tion on both the stage at diagnosis and of different treatment
regimens among cases. We have conducted such an analysis
for cases resident in the former Yorkshire Regional Health
Authority area using data obtained from the Northern and
Yorkshire Cancer Registry and Information Service (NYCRIS).
This area covers a socially diverse, stable population of
approximately 3.6 million.
MATERIALS AND METHODS
Analysis of mortality
The Office for National Statistics data on breast cancer deaths for
residents in the former Yorkshire Regional Health Authority, by
age and year, were obtained from NYCRIS. Mortality rates and
their confidence intervals were age-standardised to the European
standard population (Doll and Cook, 1967). A total of 20489
deaths by age and 3-year calendar periods starting in 1976–1978
were separated into those occurring among cases diagnosed in the
3 years preceding death (short-term survivors, 0–2 years of
survival), those among medium-term survivors (diagnosed 3–4
years before death) and those among longer-term survivors. As
Received 15 September 2003; revised 1 December 2003; accepted 1
December 2003
*Correspondence: Dr P Pisani, Unit of Descriptive Epidemiology,
International Agency for Research on Cancer, 150 Cours Albert-Thomas,
Lyons, France; E-mail: Pisani@iarc.fr
British Journal of Cancer (2004) 90, 652–656
& 2004 Cancer Research UK All rights reserved 0007– 0920/04 $25.00
www.bjcancer.com
E
p
i
d
e
m
i
o
l
o
g
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that occurred in 1975–1978 could not be categorised by survival time.
Analysis of survival
Incidence data for primary female breast cancer (ICD10¼C50) for
the Yorkshire RHA population were extracted from the NYCRIS
database for all completed years of registration from 1982 to 1999
(35739 cases). We limited the survival analyses to cases diagnosed
from 1982 onwards, in order to compare two periods of similar
duration for women diagnosed during the 1980s, when mortality
was still on the increase, and the 1990s when mortality declined.
We excluded a further 507 cases recorded only on death certificate
information or diagnosed at autopsy. Diagnoses of second primary
cancers in the same patient (2711) were also excluded, leaving a
total of 32521 new diagnoses.
Tumour size, presence or absence of positive lymph nodes and
of distant metastases were used to assign cases to one of the
four standard stage groupings (Beahts et al, 1988). This was
possible for 7997 (25%) of the cases. Partial TNM information was
available for an additional 8912 (27%) cases, which were classified
into two intermediate groups, one (termed I/II) including any
tumours with size T1 and the other (termed II/III) including any
tumours with size T2 or larger; both these groups excluded cases with
evidence of metastases. Owing to the high correlation between
tumour size and other parameters of stage (Duffy et al, 1991; Crisp
et al,1 9 9 3 ) ,i tw a sa s s u m e dt h a tm o s tc a s e si ng r o u pI / I Iw e r e
either stage I or II and that group II/III included mainly stages II and
III. The residual proportion of cases with no or insufficient
information on stage was 48%.
Therapy administered within the first 6 months of diagnosis was
recorded (yes or no) separately for surgery, radiotherapy, che-
motherapy and hormonal therapy. Data were over 98% complete for
these four indicator variables. Since information on stage was
available for only 52% of cases, we could not evaluate the incidence
trends by stage. The 3-year survival of cases incident in 1991–1999
was compared with that of cases incident in 1982–1990 using Cox
regression. The extent of improvement in short-term survival due to
advanced diagnosis was then evaluated by the effect of adjustment
for stage. Improvements in survival due to treatment factors were
also evaluated, adjusting by the indicator variables for each of
the therapeutic modalities. Hazard ratios (HR) comparing the above
two periods were calculated separately for the three age groups o50,
50–64 and 65þ years, adjusted for age (single year) within each
interval.
RESULTS
Trends in mortality rates
Age-standardised mortality rates (ASMRs) by calendar periods of 3
years and years since diagnosis are shown in Figure 1. The decline
of mortality began around 1985. Age-standardised mortality rates
in 1982–1984 to 1997–1999, overall and by survival time, are given
in Table 1. Overall, the rate decreased by 11 deaths/100000
population, corresponding to 26% of the initial rate. This decrease
was largely confined to short- and medium-term survivors (cases
diagnosed within the 5 years preceding death), with statistically
significant declines of around 35%. The decrease in longer-term
survivors, although statistically significant, was much smaller in
magnitude, around 12%. We observed the same pattern of
mortality reductions over time within each of the three age groups
o50, 50–64 and 65þ years (details not shown). Comparison of
the two time periods considered in the survival analysis (see
below) showed a reduction in the ASMR from 38.8/100000 in
1982–1990 to 32.8/100000 in 1991–1999, with statistically
significant declines of around 35%.
Trends in stage distribution
Figure 2 shows the relative distribution of defined stages and of
undetermined stage, by age and time period. The proportion of
patients diagnosed with advanced stage disease (II/III–IV)
decreased substantially in the 1990s at all ages, by 40% on average.
The proportion of cases with no recorded information on stage
was the lowest (33% on average in 1982–1999) in the 50–64 age
group, particularly in the second period when this group was the
target of mammography screening. The proportions with missing
stage data were similar in the other two age groups, 53% in o50
years and 57% in 65þ years. The stage-specific 5-year survival
rates, estimated by the Kaplan–Meier method, are shown in
Table 2 for 1982–1990 and 1991–1999. The survival of patients in
group I/II was intermediate between that of stages I and II, and
survival in group II/III was intermediate between stages II and III
in both time periods. For cases incident in the 1980s, the 5-year
survival of staged cases was significantly lower than that of
unstaged cases (0.52%, 95% c.l. 0.50–0.53 vs 0.60, 95% c.l. 0.59–
0.61). Vice versa, survival of cases diagnosed in the 90s was
superior among those staged (0.70%, 95% c.l. 0.69–0.71),
compared to those unstaged (0.58%, 95% c.l. 0.57–0.60). Survival
of cases in the second time period was improved for every stage
except stage IV.
3-year survival comparison
Overall, patients diagnosed in the period 1982–1990 had a 3-year
survival rate of 69%. This increased to 90% for patients diagnosed
in 1991–1999. Table 3 shows the hazard ratios (3-year survival) of
cases diagnosed in 1991–1999 compared with cases diagnosed in
1982–1990. Overall, there was a statistically significant improve-
ment in the later time period (HR¼0.75, 95% CI 0.71–0.78), but
was substantially reduced after adjustment for stage (HR¼0.95,
95% CI 0.90–0.99).
When analysed by age group, the improvement in prognosis was
more evident in women below 65 years of age, and was highest in
the age group eligible for screening, 50–64 years (HR¼0.51, 95%
CI 0.47–0.57). The difference between the two time periods was
lowest in the 65þ years age group, but remained statistically
significant (HR¼0.83, 95% CI 0.79–0.88). When stage was
included in the model, the HR differences between the two time
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Figure 1 Age-standardised mortality rates for female breast cancer by
time period and years from diagnosis, Yorkshire.
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yperiods persisted below age 65 years, although they were reduced
to 0.80 (95% CI 0.70–0.91) below 50 years and 0.68 (95% CI 0.61–
0.76) at 50–64 years. In women 65þ years, stage at diagnosis
accounted for all the improvement in survival, and the adjusted
HR was 1.01 (95% CI 0.96–1.08).
Changes in treatment patterns
Figure 3 shows for the three age groups, only a relatively small
increase between 1982–1990 and 1991–1999 in the proportion of
breast cancer patients undergoing surgery, 90–95% in women
o65 years and 60–70% in women 65þ years. The small increase
was very similar for the proportion of women receiving radio-
therapy. In contrast, there were substantial increases in the use of
systemic therapy between the two time periods (Figure 4). In the
earlier period, approximately 50% of cases less than 50 years did
not receive any systemic therapy, 10% had chemotherapy only and
40% had hormone therapy, that in 9% of the cases was combined
with chemotherapy. By the 1990s, only 13% of cases in this age
group had no systemic therapy, and the proportion treated with
both hormone and chemotherapy increased to 41%. In all, 40% of
cases aged 50–64 years in the 1980s received no systemic therapy,
and hormone therapy was more common among those treated
(56%). The proportion of cases that did not receive systemic
therapy was reduced to 10% in the 1990s, almost entirely due to
increased use of hormone therapy. In cases over 65 years, the use
Table 2 Number of female breast cancer cases and proportion surviving
5 years (Kaplan–Meier estimate) by stage at diagnosis
a – Yorkshire,
1982–1999
Stage No.
Proportion surviving
5 years 95% c.l.
Cases incident in 1982–1990
I 181 0.86 (0.80–0.90)
I/II 842 0.84 (0.82–0.87)
II 122 0.66 (0.57–0.74)
II/III 1761 0.63 (0.61–0.66)
III 69 0.39 (0.28–0.50)
IV 1395 0.12 (0.10–0.13)
All stages 4370 0.52 (0.50–0.53)
Insufficient or no information 10460 0.60 (0.59–0.61)
Cases incident in 1991–1999
I 685 0.91 (0.94–0.98)
I/II 3518 0.86 (0.85–0.88)
II 3434 0.73 (0.70–0.75)
II/III 2195 0.67 (0.65–0.69)
III 749 0.61 (0.56–0.66)
IV 1111 0.15 (0.13–0.18)
All stages 11692 0.70 (0.69–0.71)
Insufficient or no information 5043 0.58 (0.57–0.60)
aSee text for stage definitions.
Table 1 Female breast cancer age-standardised mortality rates (ASMR) per 100000 and 95% confidence intervals in 1982–1984 and 1997–1999 by
years since diagnosis – Yorkshire (former Regional Health Authority Area)
ASMR
Years since diagnosis 1982–1984 1997–1999 Change % Change P
0–2 18.7 12.5  6.2  33.2 0.000
(17.6-19.8) (11.6-13.4)
3–4 7.2 4.4  2.8  38.9 0.000
(6.5-7.9) (3.9-5.0)
5+ 14.3 12.6  1.7  11.9 0.008
(13.3-15.2) (11.7-13.4)
All 40.1 29.5  10.6  26.5 0.000
(38.5-41.8) (28.2-30.8)
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Figure 2 Relative distribution of stage at diagnosis and proportion of
cases of undetermined stage for female breast cancer by time period and
age group, Yorkshire.
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Figure 3 Percent of cases receiving surgery and radiotherapy for female
breast cancer by time period and age group, Yorkshire.
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hormone therapy, that was already common in the 1980s (70% of
the cases treated), increased to 90% of all cases. In summary, the
most important change observed over time was the increase in the
proportion of cases receiving hormone therapy particularly under
age 65 years. Despite these substantial changes over time,
adjustment for chemotherapy and hormone treatment had no
statistically significant effect in any age group or overall (Table 3).
DISCUSSION
Recent time trends in the incidence and mortality of breast cancer
in Yorkshire follow the general pattern of that reported for the UK
overall (Northern & Yorkshire Cancer Networks, 1999; Blanks et al,
2000). Incidence and mortality trends have been diverging since
the mid-1980s, indicating important improvements in the prog-
nosis of the disease. The aim of this study was to evaluate the
causes of the decline in mortality, taking advantage of the
information on stage and treatment available in the NYCRIS
database.
Stage-specific and treatment-specific trends of mortality rates
would be the ideal measures to separate the impact of early
diagnosis and treatment, but this would require complete
information throughout the period studied. Owing to the
incompleteness of data on stage, we used short-term survival as
the outcome measure as recently proposed (Stockton et al 1997).
In the presence of trends towards early diagnosis, survival time is
artificially prolonged by lead time, producing spurious improve-
ments of prognosis over time. Mortality per se is, in contrast, not
affected by lead time, and thus the observed overall 26% decline is
an unbiased finding. We have also shown that the decline in breast
cancer mortality in Yorkshire from 1982 to 1984 appears to be
largely confined to short- and medium-term survivors in each of
the three age groups considered. Although these analyses are still
biased by lead time (when diagnosis is advanced, more deaths are
attributed to longer survival), an average lead time of several years
would be required to account for all the observed effect. We
believe, therefore, that the mortality decline is primarily related to
prognostic improvements in the 5 years after diagnosis. This
should be investigated further by investigation of the quantitative
impact on mortality of shifts in stage and changes in treatment
patterns, taking into account the results of randomised trials.
Quantitative estimates using different scenarios would help a full
interpretation of our results as well as the general trends. We plan
to conduct further research on this subject using simulations.
In the 1980s, a large proportion of cases were diagnosed at
advanced stages, and this proportion was reduced substantially in
the subsequent decade (Figure 2). Overall, nearly all the difference
in survival was accounted for by stage adjustment, and the benefit
in terms of reduction of mortality was evident at all ages. Very
similar results were reported for East Anglia (Stockton et al, 1997).
In our data, a residual advantage for cases below age 65 years and
diagnosed in the 1990s persisted and remained statistically
significant after adjustment for clinical stage.
We also found quite different patterns of treatment in the two
time periods, with substantial increases in the use of systemic
therapy. These changes did not, however, explain the residual
short-term improvements over time. This lack of effect on
mortality is consistent with findings from a major overview of
randomised trials of early breast cancer, in which the reduction in
mortality at 3 years of follow-up for treated cases was less than 3%
(Early Breast Cancer Trialists’ Collaborative Group, 1998a,b). One
would not, therefore, expect to detect the effects of systemic
therapy in 3 years of follow-up in a much more heterogeneous
population of cases that includes advanced disease and not all
benefiting from optimal treatment. Short-term effects of systemic
therapy were not detected in other population-based data (Nab
et al, 1994; Stockton et al, 1997). Our data also suggest a worse
survival, albeit not statistically significant, associated with systemic
therapy in the youngest age group. The most likely interpretation
of this observation is that this is the result of a tendency to
administer chemotherapy and endocrine therapy to cases of
poorer prognosis within our broad stage categories.
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Figure 4 Proportions of cases receiving chemotherapy (CT) and/or
hormone therapy (HT) for female breast cancer by time period and age
group, Yorkshire.
Table 3 Proportional hazard ratios (Cox regression) for 3-years survival from female breast cancer for patients diagnosed in 1991–1999 compared to
1982–1990 – Yorkshire
Adjustments
Age group No. of cases Age (single years) Age & stage
Age, stage, hormone treatment,
chemotherapy
All* 32521 0.75 0.95 0.95
(0.71–0.78) (0.90–0.99) (0.91–1.00)
o50 years 7347 0.71 0.80 0.71
(0.63–0.80) (0.70–0.91) (0.61–0.83)
50–64 years 10947 0.51 0.68 0.65
(0.47–0.57) (0.61–0.76) (0.59–0.74)
65+ years 14227 0.83 1.01 1.06
(0.79–0.88) (0.96–1.08) (1.00–1.13)
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younger cases between the two time periods. There was a large
number of unstaged cases in our data set and, even among those
staged, there may be inaccuracies. The proportion of unstaged
cases decreased substantially over time, and it may be that the
process of stage characterisation has similarly improved over time.
This could, therefore, result in a differential stage misclassification
bias such that, in the later time period, cases are more likely to be
categorised as advanced cancers that, in the earlier time period,
would be considered as ‘early’. This phenomenon, when deter-
mined by changes in clinical practice, has been termed as ‘stage
migration’ (Feinstein et al, 1985). Improved accuracy of stage
description over time would result in an apparent stage-specific
improvement in survival. This phenomenon would be the greatest
for cases in the screening age group. The standard classification of
stage describes the progression of clinical disease, but does not
make provision for the many subclinical tumours that are detected
by mammography. If invasive, these are pooled with stage I
clinically detectable tumours. In cases 50–64 years of age
diagnosed in the 1990s, the stage I group includes many invasive
screen-detected subclinical cancers, whose survival is prolonged by
lead time. Indeed, it is among these cases that the largest difference
persists.
The second factor could be a real initial, albeit small, effect of
screening that was not addressed in our analysis. A change in the
mortality trend began before the first round of mammography
examinations was completed in 1994. Mammography itself cannot
therefore be the cause of the initial reduced risk of death, but it
may account for some of the decline from 1995 onwards. Direct
evidence that the NHS programme reduced the incidence of
advanced disease as well as the mortality rate in women 50–54
years when first screened has been recently reported (Threlfall et al,
2003). Clearly, this would not apply directly to the age group o50
years, who were not invited for mammography although
improvements in breast cancer prognosis, across all age groups,
are likely to result from the implementation of the national
screening programme that facilitated generalised improvements in
breast cancer treatment and care.
In summary, we attribute most of the decline of mortality in
Yorkshire in the 1990s to a generalised shift towards more
favourable stages at diagnosis and earlier treatment. This is not
predominantly an effect of screening. We also describe important
changes in treatment regimens in the two periods compared,
which, however, had no impact on short-time survival. Continuing
declines in mortality can be expected in the current decade as a
result of the long-term effects of both mammography screening
(IARC, 2002; Threlfall et al, 2003) and increased use of systemic
therapy (Early Breast Cancer Trialists’ Collaborative Group,
1998a,b).
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